Sofinnova Investments, Inc.

Position in RARE — Ultragenyx Pharmaceutical Inc.

CIK 1631134 Menlo Park, CA

Back to RARE Full portfolio

Position in RARE

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$65,906,353

+$63,990,453 QoQ

Shares Held

3,145,888

+3676.6% QoQ

Ownership

3.19%

of shares outstanding

% of Portfolio

3.30%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Dec 2025

2 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in RARE Over Time

Shares Held

Position Value (USD)

Derivatives in RARE

reported options exposure · as of Mar 31, 2026

CallValue

$7,332,500

CallShares

350,000

PutValue

PutShares

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

Sofinnova Investments, Inc. holds $1,145,092,748 across 48 Biotechnology names. RARE ranks #4 (5.8% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	JAZZ	Jazz Pharmaceuticals plc	598,327	$113,113,719
2	VERA	Vera Therapeutics, Inc.	2,793,987	$112,402,097
3	COGT	Cogent Biosciences, Inc.	2,113,551	$81,350,577
4	RARE	Ultragenyx Pharmaceutical Inc. This page	3,145,888	$65,906,353
5	RAPP	Rapport Therapeutics, Inc.	1,904,408	$59,588,926
6	INSM	INSMED Inc	346,075	$56,590,184
7	BMRN	Biomarin Pharmaceutical Inc	781,982	$44,174,163
8	CELC	Celcuity Inc.	366,175	$41,795,214

All Filings in RARE

Export CSV

3 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$7,332,500	350,000	-88.9%	Call	Sole	2026-05-15
2026-03-31	$65,906,353	3,145,888	+3676.6%	Shares	Sole	2026-05-15
2025-12-31	$1,915,900	83,300	—	Shares	Sole	2026-02-13
No filing history on record for this holder in this stock.